On aspirin treatment but not baseline thromboxane B2 levels predict adverse outcomes in patients with acute coronary syndromes
Journal of Thrombosis and Haemostasis, 07/16/2012
Matsuura E et al. – The clinical benefits of acetylsalicylic acid (ASA) in the primary or secondary prevention of cardiovascular disease are attributed to its ability to inhibit the generation of platelet derived thromboxane A2, a potent vasoconstrictor and promoter of platelet aggregation. Low doses of ASA irreversibly acetylate the platelet cyclooxygenase–1 (COX–1) pathway and are capable of blocking over 95% of subsequent thromboxane production for the entire life cycle of platelets.